0

0

0

0

0

0

0

0

0

market | IST

Standout Brokerage Report: Why Credit Suisse is bearish on Sun Pharma

Mini

Credit Suisse has maintained its underperform rating on Sun Pharmaceutical Industries with a target price of Rs 420. The brokerage firm believes that the market is ignoring a significant competition to Sun Pharma’s two key drugs Cequa and Ilumya. CNBC-TV18’s Nimesh Shah has more details.

Credit Suisse has maintained its underperform rating on Sun Pharmaceutical Industries with a target price of Rs 420. The brokerage firm believes that the market is ignoring a significant competition to Sun Pharma’s two key drugs Cequa and Ilumya. CNBC-TV18’s Nimesh Shah has more details.
To watch other videos in this series, click on the Standout Brokerage Report tab below.